Lasvic tablets 75 mg for bacterial infections (antibiotic, quinolone, lascufloxacin)

Are Lasvic tablets 75 mg effective for bacterial infections (antibiotic, quinolone,  lascufloxacin)?

CURRENTLY UNAVAILABLE

Since 2019, Lasvic tablets, containing lascufloxacin, have been approved for clinical use in Japan, primarily targeting respiratory and otorhinolaryngological infections. The mechanism of action of Lasvic tablets revolves around their potent antibacterial properties, especially against the major pathogens responsible for respiratory tract infections. This drug's efficacy stands out as it surpasses conventional quinolones, showing superior activity, particularly against oral streptococci and anaerobic bacteria, which are increasingly recognized as key culprits in community-acquired pneumonia.

 

Lascufloxacin, a fluoroquinolone antibiotic, works by inhibiting the DNA gyrase and topoisomerase IV enzymes, both crucial for bacterial DNA replication and repair. This mechanism effectively halts bacterial growth and division. The dual targeting of these essential enzymes in the bacterial DNA replication process enhances Lasvic's effectiveness against a broad spectrum of bacterial strains implicated in respiratory and otorhinolaryngological infections.

 

Clinical studies have shown that Lasvic tablets effectively alleviate symptoms and clinical manifestations associated with respiratory infections. The drug demonstrates robust activity against pathogens like Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis, which are common in respiratory infections. In an article called “An overview of oral lascufloxacin, a novel quinolone antibiotic” Japanese researchers also confirmed that lascufloxacin showes better activity than conventional quinolones against oral streptococci and anaerobes which have been identified as the causative bacteria of community-acquired pneumonia. 

 

Package details: 50 tablets

Dosage and administration: Adults should take 1 tablet (75 mg of the active principle) at a time, once a day.

Active components: lascufloxacin hydrochloride

Therapeutic effect: treatment of respiratory infections and otorhinolaryngological infections, including following:

community-acquired pneumonia,

Contraindications: do not use for patients with liver dysfunction, convulsive diseases such as epilepsy or a history of these diseases, cardiac diseases such as arrhythmia or ischemic heart disease, myasthenia gravis. Do not use for patients with aortic aneurysm or aortic dissection, or a history or family history of those, or Marfan syndrome, etc. Do not use for pregnant, possibly pregnant or breastfeeding women.

Important information: Store in a dry cool place, out of reach of children. Do not expose to sunlight or heat. If allergic symptoms occur, discontinue use.